Literature DB >> 2221853

Newer uses of intravenous immunoglobulins as anti-infective agents.

J E Pennington1.   

Abstract

Mesh：

Substances：

Year:  1990        PMID： 2221853      PMCID： PMC171853          DOI： 10.1128/AAC.34.8.1463

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  23 in total

1.  Intravenous immunoglobulin for prevention of sepsis in preterm and low birth weight infants.

Authors:  K N Haque; M H Zaidi; S K Haque; H Bahakim; M el-Hazmi; M el-Swailam
Journal:  Pediatr Infect Dis       Date:  1986 Nov-Dec

2.  Clinical safety of intravenous immune globulin and freedom from transmission of viral disease.

Authors:  R H Rousell
Journal:  J Hosp Infect       Date:  1988-08       Impact factor: 3.926

3.  Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients.

Authors:  G M Schmidt; A Kovacs; J A Zaia; D A Horak; K G Blume; A P Nademanee; M R O'Donnell; D S Snyder; S J Forman
Journal:  Transplantation       Date:  1988-12       Impact factor: 4.939

4.  Elimination of infectious retroviruses during preparation of immunoglobulins.

Authors:  G Mitra; M F Wong; M M Mozen; J S McDougal; J A Levy
Journal:  Transfusion       Date:  1986 Jul-Aug       Impact factor: 3.157

5.  Bacterial infections in human immunodeficiency virus-infected children.

Authors:  K Krasinski; W Borkowsky; S Bonk; R Lawrence; S Chandwani
Journal:  Pediatr Infect Dis J       Date:  1988-05       Impact factor: 2.129

Review 6.  Clinical uses of intravenous immunoglobulins.

Authors:  S A Berkman; M L Lee; R P Gale
Journal:  Ann Intern Med       Date:  1990-02-15       Impact factor: 25.391

7.  Reduction of infection frequency by intravenous gammaglobulins during intensive induction therapy for small cell carcinoma of the lung.

Authors:  R E Schmidt; J H Hartlapp; D Niese; H J Illiger; I Stroehmann
Journal:  Infection       Date:  1984 May-Jun       Impact factor: 3.553

8.  Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial.

Authors:  T Calandra; M P Glauser; J Schellekens; J Verhoef
Journal:  J Infect Dis       Date:  1988-08       Impact factor: 5.226

9.  Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome.

Authors:  H C Lane; H Masur; L C Edgar; G Whalen; A H Rook; A S Fauci
Journal:  N Engl J Med       Date:  1983-08-25       Impact factor: 91.245

10.  Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency.

Authors:  J Björkander; C Cunningham-Rundles; P Lundin; R Olsson; R Söderström; L A Hanson
Journal:  Am J Med       Date:  1988-01       Impact factor: 4.965
View more
  5 in total

1.  Preclinical immunoprophylactic and immunotherapeutic efficacy of antisera to capsular polysaccharide-tetanus toxoid conjugate vaccines of Vibrio vulnificus.

Authors:  S J Devi; U Hayat; J L Powell; J G Morris
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

2.  Effective combination therapy for invasive pneumococcal pneumonia with ampicillin and intravenous immunoglobulins in a mouse model.

Authors:  L De Hennezel; F Ramisse; P Binder; G Marchal; J M Alonso
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

3.  Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B.

Authors:  J Mukherjee; L S Zuckier; M D Scharff; A Casadevall
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

4.  Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice.

Authors:  S Mukherjee; S Lee; J Mukherjee; M D Scharff; A Casadevall
Journal:  Infect Immun       Date:  1994-03       Impact factor: 3.441

Review 5.  Antibody-based therapies for emerging infectious diseases.

Authors:  A Casadevall
Journal:  Emerg Infect Dis       Date:  1996 Jul-Sep       Impact factor: 6.883
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.